Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 3, 2003 - Issue 1
Submit an article Journal homepage
15
Views
0
CrossRef citations to date
0
Altmetric
Review

Cost-effectiveness of hepatitis C screening of blood donations

Sandrine Loubiere French National Institute of Medical Research, INSERM U379, 23 rue Stanislas Torrents, 13006 Marseilles, France. [email protected]
&
Jean-Paul Moatti French National Institute of Medical Research, INSERM U379, 232 boulevard Sainte Marguerite, 13273 Marseilles, France. [email protected]
Pages 47-55 | Published online: 09 Jan 2014

References

  • Kuo G, Choo Q, Alter H etal An assay forcirculating antibodies to a major etiologic virus of human nonA nonB hepatitis. Science 244,362–367 (1989).
  • Nalpas B, Desendos JC, Delarocque- Astagneau E, Drucker J. State of epidemiological knowledge and national
  • National Institutes of Health. Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology26, 2S-10S (1997).
  • Tong M, el-Farra N, Reikes A, Co RL. Clinical outcomes after transfussion-associated hepatitis C. N Engl. J. Med 332, 1463–1466 (1995).
  • Seeff LB. Why is there such difficulty in defming the natural history of hepatitis C? 7iansfusion 40,1161–1164 (2000).
  • Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 351 214–215 (1998).
  • Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 29, 1596–1601 (1999).
  • Donahue J, Munoz A, Ness P et al The declining risk of post-transfusion hepatitis C virus infection. N Engl. J. Med. 327, 369–373 (1992).
  • Barrera JM, Francis B, Ercilla G etal. Improved detection of antiHCV in post-transfusion hepatitis by a third-generation ELISA. VoxSang. 68,15–18 (1995).
  • Gerlich WH, Caspari G. Hepatitis viruses and the safety of blood donations. J. Viral Hepat. 6,6–15 (1999).
  • Aach RD, Stevens CE, Hollinger FB eta]. Hepatitis C virus infection in post-transfusion hepatitis: an analysis with first and second generation assays. N Engl. J. Med. 325,1325-1328 (1991).
  • Dawson G, Lesniewski R, Stewart J eta]. Detection of antibodies to hepatitis C virus in US blood donors. J. Clin. Mcrob. 29, 551–556 (1991).
  • Esteban J, Gonzales A, Hernandez J etal. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N. Engl. Med. 323,1107–1112 (1990).
  • Kao JH, Lai MY, Hwang YT et a/. Chronic hepatitis C without antihepatitis C antibodies by second-generation assay. A clinicopathologic study and demonstration of the usefulness of a third-generation assay. Sc].Dir Dis. 41,161–165 (1996).
  • Lavanchy D. Evaluation of a new automated third-generation antiHCV enzyme immunoassay. J. Clin. Lab. Anal 10,269–276 (1996).
  • Schreiber G, Bush M, Kleinman S, Koreliz J for the retrovirus epidemiology donor study. The risk of transmission-transmitted viral infections. N. Eng/. J. Med. 334, 1685–1690 (1996).
  • Pillonel J, Saura C, Courace AM. Prevalence of HIV, HTLV and hepatitis B and C virus in blood donors in France, 1992–1996. 7iansfus. Clin. Biol. 5,305-312 (1998).
  • Kleinman S, Busch M, Korelitz J, Schreiber G. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus. Med. Rev11,155–172 (1997).
  • Couroucé AM, Pillonel J. Estimation of risk of virus transmission in hepatitis B and C and human retrovirus via transfusion of labile blood derivatives. 7iansfus. Clin. Biol. 3,858-862 (1996).
  • Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JA/V/A 276,1253–1258 (1996).
  • Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JA/V/A 276,1172–1177 (1996).
  • Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J. Health Econ. 16,1–31 (1997).
  • Weinstein MC, Manning WG. Theoretical issues in cost-effectiveness analysis. J. Health Econ. 16,121–128 (1997).
  • Garber A. Advances in cost-effectiveness analysis of health interventions. In: Handbook of Health Economics. Culyer AJ, Newhouse JP (Eds), Elsevier, Amsterdam, The Netherlands (2000).
  • Sonnenberg F, Beck J. Markov models in medical decision making: A practical guide. Med Decis. Making 13,322–338 (1993).
  • Kenny-Walsh E. The natural history of hepatitis C virus infection. Clin. Liver Dis. 5,969–977 (2001).
  • Seeff LB. Natural history of hepatitis C. AIThI Med. 107,10S-15S (1999).
  • Karlsson G, Johannesson M. Decision roles of cost-effectiveness analysis. PbarmacoEconomics9, 113–120 (1996).
  • Lapane K, Jakiche A, Sugano D, Weng C, Carey W Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National hepatitis surveillance group. Am.j Gastroenterol 93,591–596 (1998).
  • •Economic evaluation of HCV screening in blood donations.
  • Sailly JC, Lebrun T, Coudeville L. Cost- effective approach to the screening of HIV, HBV, HCV, HTLV in blood donors in France. Rev Epidemiol Sante Publ 45, 131–141 (1997).
  • •Economic evaluation of HCV screening in blood donations.
  • Vergnon P, Colin C, Jullien AM eta]. Medical and economic evaluation of donated blood screening for hepatitis C and non-A, non-B, non-C hepatitis. Rev Epidemiol Sante Publ 44,66–79 (1996).
  • •Economic evaluation of HCV screening in blood donations.
  • Rotily M, Loubiere S, Nixon J etal. Should hepatitis C be screened? Socioeconomic analysis of different screening strategies for chronic hepatitis C in French population. Gastroenteml Clin. Biol. 21, S33–40 (1997).
  • •Economic evaluation of HCV screening in high-risk groups and the general population.
  • Busch MP, Korelitz JJ, Kleinman SH etal Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion 35,903–910 (1995).
  • ••Economic evaluation of HCV screening inblood donations.
  • Poynard. T, Marcellin P, Lee SS etal. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group Lancet352, 1426–1432 (1998).
  • POi S, Couzigou P, Bourliere M etal. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non- responders to a previous treatment. Hepatol 31,1–7 (1999).
  • McHutchison JG, Gordon SC, Schiff ER etal. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl. J. Med. 339,1485-1492 (1998).
  • Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl. J. Med. 339,1493-1499 (1998).
  • Loublere S, Rotily M, Portal I, Bourlfere M, Moatti J. Evaluation économique des strategies de dépistage de l'hepatite chronique C. Med. Mal Infect. 29,337–344 (1999).
  • •Economic evaluation of HCV screening in intravenous drug users and the general population.
  • Djossou F, Salmi LR, Lawson-Ayayi S etal Cost-benefit analysis of screening strategies by human immunodeficiency virus in French blood donors. 7iansfus. Clin. Biol. 6,180-188(1999).
  • ••Economic evaluation of HIV screening inblood donations.
  • Loublère S, Rotly M, Durand-Zaleski I, Costagliola D. Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. Vox Sang. 80,199-204 (2001). Economic evaluation of HCV screening in blood donations.
  • Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion 40, 1182–1191 (2000). Economic evaluation of HCV screening in blood donations.
  • Koff RS. Cost-effectiveness of combined interferon and ribavirin versus interferon alone. Gun. Liver Dis. 3, 827–841 (1999).
  • Loubiere S, Rotily M, Moatti JP. Medico- economic assessment of the therapeutic management of patients with hepatitis C. Gastroenteml Gin. Biol. 24, 1047–1051 (2000).
  • Wong JB, Poynard T, Ling MET, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J. Gastroenterol 95, 1524–1530 (2000).
  • ShacIdey P, Donaldson C. Should we use willingness to pay to elicit community preferences for healthcare?: New evidence from using a 'marginal' approach. J. Health Econ. 21, 971–991 (2002).
  • Dolan P, Edlin R. Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis? J. Health Econ. 21, 827–843 (2002).
  • Bala MV, Wood LL, Zarkin GA eta]. Valuing outcomes in healthcare: a comparison of willingness to pay and quality-adjusted life-years. J. Gun. 43idemiol. 51, 667–676 (1998).
  • Brouwer VVB, Koopmanschap MA. On the economic foundations of CEA. Ladies and gentlemen, take your positions! J. Health Econ. 19, 439–459 (2000).
  • Dolan P. The measurement of individual utility and social welfare. J. Health Econ. 17, 39–52 (1998).
  • Johannesson M. On aggregating QALYs: a comment on Dolan. J. Health Econ. 18, 381–386 (1999).

Websites

  • National Health Service (2002). Centre for Reviews and Dissemination, University of York, York, UK. www.agatha.york.ac.uk

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.